DOP2022000027A - Síntesis de un inhibidor de calicreína plasmática a escala de proceso - Google Patents
Síntesis de un inhibidor de calicreína plasmática a escala de procesoInfo
- Publication number
- DOP2022000027A DOP2022000027A DO2022000027A DO2022000027A DOP2022000027A DO P2022000027 A DOP2022000027 A DO P2022000027A DO 2022000027 A DO2022000027 A DO 2022000027A DO 2022000027 A DO2022000027 A DO 2022000027A DO P2022000027 A DOP2022000027 A DO P2022000027A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- kallicrein
- inhibitor
- plasma
- synthesis
- process scale
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962883396P | 2019-08-06 | 2019-08-06 | |
| PCT/US2020/044921 WO2021026182A1 (en) | 2019-08-06 | 2020-08-05 | Process-scale synthesis of a plasma kallikrein inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2022000027A true DOP2022000027A (es) | 2022-05-31 |
Family
ID=74504082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2022000027A DOP2022000027A (es) | 2019-08-06 | 2022-02-03 | Síntesis de un inhibidor de calicreína plasmática a escala de proceso |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12503443B2 (enExample) |
| EP (1) | EP4010320A4 (enExample) |
| JP (1) | JP7626751B2 (enExample) |
| KR (1) | KR102928815B1 (enExample) |
| CN (1) | CN114206839B (enExample) |
| AR (1) | AR119617A1 (enExample) |
| AU (1) | AU2020324422B2 (enExample) |
| BR (1) | BR112022002060A2 (enExample) |
| CA (1) | CA3149176A1 (enExample) |
| CL (2) | CL2022000264A1 (enExample) |
| CO (1) | CO2022002392A2 (enExample) |
| CR (1) | CR20220092A (enExample) |
| DO (1) | DOP2022000027A (enExample) |
| EC (1) | ECSP22016209A (enExample) |
| GE (2) | GEAP202515893A (enExample) |
| IL (1) | IL290113B2 (enExample) |
| JO (1) | JOP20220021A1 (enExample) |
| MX (1) | MX2022001608A (enExample) |
| PE (1) | PE20221009A1 (enExample) |
| PH (1) | PH12022550221A1 (enExample) |
| PY (1) | PY2042865A (enExample) |
| TN (1) | TN2022000028A1 (enExample) |
| TW (1) | TWI881995B (enExample) |
| UA (1) | UA130182C2 (enExample) |
| UY (1) | UY38826A (enExample) |
| WO (1) | WO2021026182A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3113772T (lt) | 2014-03-07 | 2020-12-28 | Biocryst Pharmaceuticals, Inc. | Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| EP4010320A4 (en) | 2019-08-06 | 2023-08-16 | Biocryst Pharmaceuticals, Inc. | Process-scale synthesis of a plasma kallikrein inhibitor |
| CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | 苏州农平科技发展有限公司 | 贝罗司他中间体的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| WO1991012779A1 (en) | 1990-02-28 | 1991-09-05 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| DE60034447T2 (de) | 2000-08-11 | 2008-02-14 | Wilex Ag | Nicht-kovalente Urokinase-und Angiogenese-Inhibitoren |
| US7038057B2 (en) | 2001-08-13 | 2006-05-02 | E.I. Du Pont De Nemours And Company | Substituted 1H-dihydropyrazoles, their preparation and use |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| KR101687743B1 (ko) | 2008-12-18 | 2016-12-19 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 살해충제로서의 테트라졸 치환된 안트라닐산 아미드 |
| CN102464701B (zh) | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
| DK2909181T3 (da) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
| LT3113772T (lt) | 2014-03-07 | 2020-12-28 | Biocryst Pharmaceuticals, Inc. | Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai |
| EP4010320A4 (en) | 2019-08-06 | 2023-08-16 | Biocryst Pharmaceuticals, Inc. | Process-scale synthesis of a plasma kallikrein inhibitor |
-
2020
- 2020-08-05 EP EP20850499.3A patent/EP4010320A4/en active Pending
- 2020-08-05 GE GEAP202515893A patent/GEAP202515893A/en unknown
- 2020-08-05 PE PE2022000188A patent/PE20221009A1/es unknown
- 2020-08-05 BR BR112022002060A patent/BR112022002060A2/pt unknown
- 2020-08-05 JP JP2022506947A patent/JP7626751B2/ja active Active
- 2020-08-05 CA CA3149176A patent/CA3149176A1/en active Pending
- 2020-08-05 IL IL290113A patent/IL290113B2/en unknown
- 2020-08-05 KR KR1020227003932A patent/KR102928815B1/ko active Active
- 2020-08-05 PH PH1/2022/550221A patent/PH12022550221A1/en unknown
- 2020-08-05 CR CR20220092A patent/CR20220092A/es unknown
- 2020-08-05 MX MX2022001608A patent/MX2022001608A/es unknown
- 2020-08-05 WO PCT/US2020/044921 patent/WO2021026182A1/en not_active Ceased
- 2020-08-05 UA UAA202200914A patent/UA130182C2/uk unknown
- 2020-08-05 JO JOP/2022/0021A patent/JOP20220021A1/ar unknown
- 2020-08-05 US US17/632,585 patent/US12503443B2/en active Active
- 2020-08-05 AU AU2020324422A patent/AU2020324422B2/en active Active
- 2020-08-05 CN CN202080055475.4A patent/CN114206839B/zh active Active
- 2020-08-05 TW TW109126552A patent/TWI881995B/zh active
- 2020-08-05 TN TNP/2022/000028A patent/TN2022000028A1/en unknown
- 2020-08-05 GE GEAP202015893A patent/GEP20257777B/en unknown
- 2020-08-06 AR ARP200102248A patent/AR119617A1/es unknown
- 2020-08-06 UY UY0001038826A patent/UY38826A/es active IP Right Grant
- 2020-08-06 PY PY202002042865A patent/PY2042865A/es unknown
-
2022
- 2022-02-01 CL CL2022000264A patent/CL2022000264A1/es unknown
- 2022-02-03 DO DO2022000027A patent/DOP2022000027A/es unknown
- 2022-02-28 CO CONC2022/0002392A patent/CO2022002392A2/es unknown
- 2022-03-03 EC ECSENADI202216209A patent/ECSP22016209A/es unknown
-
2023
- 2023-03-30 CL CL2023000942A patent/CL2023000942A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000942A1 (es) | Síntesis de un inhibidor de calicreína plasmática a escala de proceso . | |
| UY38837A (es) | Proceso de elaboración de moduladores de cftr | |
| CO2019010035A2 (es) | Síntesis de inhibidor de mcl-1 | |
| ECSP19083967A (es) | Compuestos antitumorales | |
| CY1125201T1 (el) | Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma) | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| CO2018013827A2 (es) | Procesos para preparar oligómeros de morfolino fosforodiamidato | |
| MX2019011412A (es) | Piperidinas como inhibidores de menina covalentes. | |
| CO2018013834A2 (es) | Procesos para preparar oligómeros de morfolino fosforodiamidato | |
| CL2024000609A1 (es) | Proceso para sintetizar derivados de naftiridina y compuestos intermedios de los mismos. | |
| MX2018003318A (es) | Derivado de biarilo y medicamento que contiene el mismo. | |
| MX2019010642A (es) | Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos. | |
| CO2020000371A2 (es) | Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos | |
| CO2020001861A2 (es) | Inhibidores de ror gamma | |
| MX2025003091A (es) | Metodo para producir derivado de heterociclideno acetamida | |
| CO2021007172A2 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| CO2018013831A2 (es) | Procesos para preparar oligómeros de morfolino fosforodiamidato | |
| CL2021000663A1 (es) | Proceso para la producción de gas de síntesis. | |
| MX2019011517A (es) | Proceso para producir analogos de anillo de arilomicina. | |
| MX2018016387A (es) | Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona. | |
| CY1121253T1 (el) | Μεθοδος παραγωγης μεγαλης κλιμακας του διυδροχλωρικου ν-[4-(1-κυκλοβουτυλοπιπεριδιν-4-υλοξυ)φαινυλ]-2-(μορφολιν-4-υλ)ακεταμιδιου | |
| CY1123076T1 (el) | Ενωσεις βενζο-ν-υδροξυ αμιδιου που εχουν αντικαρκινικη δραστikothta | |
| CO2022008102A2 (es) | Proceso e intermediarios para la producción de fórmula (i) | |
| EA201991629A3 (ru) | Способ | |
| UY4762U (es) | Forros adherentes para zapatos |